Metastatic melanoma is associated with a poor prognosis, but recent breakthroughs in tumor biology and immune regulation have led tothe development of agents that could change clinical practice, according to a panel of experts who participated in a recent OncLive PeerExchange.
MRV Research
New Drugs To Treat Drug Resistant Melanoma Discovered by Researchers
In a recent study published in the journal Cancer Cell scientists at The Institute of Cancer Research, London, and the Cancer Research UK Manchester Institute, found a new family of drugs, panRAF inhibitors, which can be efficiently used to treat melanoma patients who developed resistance to BRAF inhibitors.
Study Finds Hair Shaft miRNA-221 Levels Can Be Used As Malignant Melanoma Biomarker
In a recent study titled “Hair shaft miRNA-221 levels as a new tumor marker of malignant melanoma”, published in The Journal of Dermatology, a team of researchers from Kumamoto University, Japan, assessed the hypothesis that hair shaft micro RNA (miR)-221 levels could be used as a marker for malignant melanoma (MM).
Vast Majority of Ophthalmologists Treating Uveal Melanoma Use Molecular Testing to Guide Patient Care
Castle Biosciences Inc. announced the publication of study results that assess current clinical practices for uveal melanoma (UM) and demonstrate the impact of molecular prognostic testing on patient management. The paper, “Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses," was published in the peer-reviewed journal Clinical Ophthalmology.